Following on from the myopia news on ACUVUE Abiliti™ Overnight Therapeutic Lenses, the FDA have given Breakthrough Device designation to Essilor Group’s Stellest spectacle lens. This lens aims to correct myopia and slow down its development in children. Myopia found in children is at the most risk of developing into a more serious condition.
The first-year trial results showed that 9 out of 10 children who wore the Essilor Stellest lens had similar or slower eye growth than children without myopia. “The “Breakthrough Device” designation for our Essilor Stellest lens is a great achievement and an illustration of its potential in slowing down the progression of myopia in children. This designation represents an important milestone in our fight against the myopia pandemic,” Norbert Gorny, Chief Operating Officer and Chief Research & Development Officer of Essilor International
Johnson & Johnson have announced FDA approval of ACUVUE Abiliti Overnight Therapeutic Lenses for managing myopia.
Myopia, also known as near-sightedness, is a common vision condition, but it is a chronic and progressive disease. In the UK, it is estimated that 1 in 3 people are affected by the condition. In childhood, myopia can occur between the ages of 6 – 13 and worsen in teenage years.
Experts suggest that children under 12 years old, with myopia, are most at risk of developing high myopia. The overnight lenses aim to temporarily reshape the cornea to help manage the disease, particularly in children. “We look forward to supporting parents and eye care professionals in their care of children with comprehensive resources, starting with Abiliti Overnight Therapeutic Lenses, and continuing with additional products and services to address the progression of myopia.” Xiao-Yu Song, MD, PhD, Global Head of Research & Development, Johnson & Johnson Vision
J&J join mark'ennovy and CooperVision who also offer contact lenses for treating Myopia.
Novartis have announced the positive 1-year results from their Phase 3 studies, which are evaluating the efficacy and safety of Beovu in diabetic macular edema (DME). This is following possible safety concerns over the risk of side effects including retinal vasculitis, retinal vascular occlusion, blurred vision and cataracts.
Experts estimate that approximately 7.7 million Americans have diabetic retinopathy and of those, about 750,000 also have DME. The studies are a clear step forward “with the data demonstrating vision gains, fluid resolution and the potential for less frequent injections for eligible patients, we are one step closer to providing DME patients with a potential new treatment option.” J. Jill Hopkins Global Development Unit Head, Ophthalmology, Novartis Pharmaceuticals.
James Pickering is our Managing Director and an eye care recruitment expert who has developed an extensive client base and candidate network. He regularly writes articles about industry developments and has received numerous recommendations from industry leaders. You can also connect with James on LinkedIn to stay up to date on the latest eye care news.